Fortress

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Wall Street Veteran Explains Why He’s “Irresponsibly” Long on Bitcoin

Source Node: https://bitcoinist.com/wall-street-veteran-explains-why-hes-irresponsibly-long-bitcoin/?utm_source=rss&utm_medium=rss&utm_campaign=wall-street-veteran-explains-why-hes-irresponsibly-long-bitcoin
Time Stamp: August 7, 2020 8:00 AM - Modified On: May 21, 2021 - Published By:
Source Cluster:
Republished By Plato

Bitcoin has gained steam over recent weeks, hitting $12,200 last weekend as buyers rushed in. Analysts say that the cryptocurrency market has room to move higher due to technicals. But from a fundamental standpoint, some argue that BTC is more bullish than ever before. Raoul Pal, the CEO of Real Vision and a Wall Street veteran, recently touched on this. He told his Twitter following on August 6th that he’s “irresponsibly long” on Bitcoin due to the fundamentals. This Ex-Goldman Sachs Exec Is “Irresponsibly” Long on Bitcoin For This Reason